Monte Rosa Therapeutics, Inc.
GLUE
$3.70
-$0.34-8.42%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 6.15M | -72.70M | -119.39M | -130.41M | -135.28M |
| Total Depreciation and Amortization | 10.17M | 10.22M | 9.61M | 9.24M | 9.07M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 12.68M | 13.08M | 13.04M | 13.92M | 12.73M |
| Change in Net Operating Assets | 5.66M | 91.40M | 39.45M | 46.25M | 54.93M |
| Cash from Operations | 34.67M | 42.00M | -57.29M | -61.00M | -58.56M |
| Capital Expenditure | -4.19M | -3.99M | -5.49M | -6.75M | -11.24M |
| Sale of Property, Plant, and Equipment | -- | -- | 0.00 | 0.00 | 62.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -150.34M | -40.46M | 6.24M | 5.37M | 89.51M |
| Cash from Investing | -154.53M | -44.45M | 741.00K | -1.38M | 78.33M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 52.30M | 52.53M | 49.21M | 50.30M | 2.84M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 46.36M | 46.36M | 74.24M | 74.24M | 24.88M |
| Cash from Financing | 98.66M | 98.89M | 123.46M | 124.54M | 27.72M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -21.21M | 96.44M | 66.91M | 62.16M | 47.49M |